HALOZYME THERAPEUTICS, INC. (HALO) Return on equity 2017–2025
HALOZYME THERAPEUTICS, INC. (HALO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
649.2%FY2025 · since FY2017: 30.2% → 649.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 649.2% | +527.1 pp |
| FY2024 | 122.1% | -213.9 pp |
| FY2023 | 336.0% | +217.0 pp |
| FY2022 | 119.0% | -85.4 pp |
| FY2021 | 204.5% | +119.0 pp |
| FY2020 | 85.5% | +164.2 pp |
| FY2019 | -78.7% | -46.4 pp |
| FY2018 | -32.3% | -62.5 pp |
| FY2017 | 30.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More HALO financial trends
HALO RevenueHALO Net incomeHALO Net marginHALO Gross profitHALO Gross marginHALO Operating incomeHALO Operating marginHALO Operating cash flowHALO Free cash flowHALO Capital expendituresHALO Stock buybacksHALO Dividends paidHALO Total assetsHALO Total liabilitiesHALO Shareholders’ equityHALO overview →